PAROXETINE

 

• 65. Lund J, Thayssen P, Mengel H et al: Paroxetine: pharmacokinetics and cardiovascular effects after oral and intravenous single doses in man. Acta Pharmacol 1982; 51:351-357.
• 66. Lundmark J, Thomsen S, Fjord-Larsen T et al: Paroxetine: pharmacokinetic and antidepressant effect in the elderly. Acta Psychiatr Scand 1989; 80(Suppl 350):76-80.
• 67. McClelland GR & Raptopoulos P: EEG and blood level of the potential antidepressant paroxetine after a single oral dose to normal volunteers. Psychopharmacology 1984; 83:327-329.
• 68. Mertens C & Pintens H: Paroxetine in the treatment of depression: a double- blind multicenter study versus mianserin. Acta Psychiatr Scand 1988; 77: 683-688.
• 69. Miller SM, Naylor GJ, Murtagh M et al: A double-blind comparison of paroxetine and placebo in the treatment of depressed patients in a psychiatric outpatient clinic. Acta Psychiatr Scand 1989; 80(Suppl 350): 143-144.
• 70. Mills KC: Serotonin syndrome: a clinical update. Med Toxicol 1997; 13:763-783.
• 71. Misri S, Kim J, Riggs KW et al: Paroxetine levels in postpartum depressed women, breast milk, and infant serum. J Clin Psychiatry 2000; 61:828-832.
• 72. Mitchell PB: Drug interactions of clinical significance with selective serotonin reuptake inhibitors. Drug Safety 1997; 17:390-406.
• 73. Monmany J, Vazquez G, Rodriguez J et al: Syndrome of inappropriate secretion of antidiuretic hormone induced by paroxetine (letter). Arch Intern Med 1999; 159:2089-2090.
• 74. Myers LB & Krenzelok EP: Paroxetine (Paxil) overdose: a pediatric focus. Vet Human Toxicol 1997; 39:86-88.
• 75. Myers LB, Dean BS & Krenzelok EP: Paroxetine (PAXIL): overdose assessment of a new selective serotonin reuptake inhibitor. Vet Human Toxicol 1994; 36: 370.
• 76. Myers LB, Dean BS, Krenzelok EP: A pediatric focus: paroxetine (Paxil) overdose (Abstract 172). J Toxicol Clin Toxicol 1995; 313:551.
• 77. Odeh M, Seligmann H & Oliven A: Severe life-threatening hyponatremia during paroxetine therapy. J Clin Pharmacol 1999; 39:1290-1291.
• 78. Ohman R, Hagg S, Carleborg L et al: Excretion of paroxetine into breast milk. J Clin Psychiatry 1999; 60:519-523.
• 79. Ohrberg S, Christiansen PE, Severin B et al: Paroxetine and imipramine in the treatment of depressive patients in psychiatric practice. Acta Psychiatr Scand 1992; 86:437-444.
• 80. Oswald I & Adam K: Effects of paroxetine on human sleep. Br J Clin Pharmac 1986; 22:97-99.
• 81. Ottervanger JP, Stricker BHCh, Huls J, et al: Bleeding attributed to intake of paroxetine (letter). Am J Psychiatry 1994; 151:781-782.
• 82. Owley T & Flaherty J: New-onset narcolepsy and paroxetine (letter). Psychosomatics 1994; 35:585.
• 83. Paul S & Sankaran SK: An unusually rapid onset of hyponatraemia following paroxetine. Aust NZ J Med 1998; 28:840.
• 84. Phillips SD: A possible paroxetin withdrawal syndrome (letter). Am J Psychiatry 1995; 152:645-646.
• 85. Popli AP, Baldessarini RJ & Cole JO: Interactions of serotonin reuptake inhibitors with tricyclic antidepressants (letter). Arch Gen Psychiatry 1994; 51:666-667.
• 86. Product Information: Ativan(R), lorazepam. Wyeth, Philadelphia, PA, 1991.
• 87. Product Information: Paxil(R), paroxetine. SmithKline Beecham Pharmaceuticals, Philadelphia, PA, 1996.
• 88. Pyke RE: Paroxetine withdrawal syndrome (letter). Am J Psychiatry 1995; 152:149-150.
• 89. Reeves RR & Bullen JA: Serotonin syndrome produced by paroxetine and low-dose trazodone (letter). Psychosomatics 1995; 36:159.
• 90. Rickels K, Amsterdam J, Clary C et al: A placebo-controlled, double-blind, clinical trial of paroxetine in depressed outpatients. Acta Psychiatr Scand 1989; 80(Suppl 350):117-123.
• 91. Romanelli F, Adler DA & Bungay KM: Possible paroxetine-induced bruxism. Ann Pharmacother 1996; 30:1246-1248.
• 92. Roth A, Akyol S & Nelson JC. Delirium associated with the combination of a neuroleptic, an SSRI, and benztropine. J Clin Psychiatry 1994; 55:492-495.
• 93. Skop BP, Finkelstein JA, Mareth TR et al: The serotonin syndrome associated with paroxetine, an over-the-counter cold remedy, and vascular disease. Am J Emerg Med 1994; 12:642-644.
• 94. Sternbach H: The serotonin syndrome. Am J Psychiatr 1992; 149:1410-1411.
• 95. Stowe ZN, Cohen LS, Hostetter A et al: Paroxetine in human breast milk and nursing infants. Am J Psychiatry 2000; 157:185-189.
• 96. USP DI Volume I Drug information for the health care professional. 20th edition, 2000; Micromedex Inc, World Color Book Services, Taunton, MA.
• 97. Vale JA: Position Statement: gastric lavage. American Academy of Clinical Toxicology/European Association of Poisons Centres and Clinical Toxicologists. Clin Toxicol 1997; 35:711-719.
• 98. Van Campen JPCM & Voets AJ: SIADH caused by paroxetine (letter). Ann Pharmacother 1996; 30:1499.
• 99. Vermeulen T: Distribution of paroxetine in three postmortem cases. J Anal Toxicol 1998; 22:541-544.
• 100. Wilson SJ, Lillywhite AR, Potokar JP et al: Adult night terrors and paroxetine. Lancet 1997; 350:185.
• 101. Zajecka J, Tracy KA & Mitchell S: Discontinuation symptoms after treatment with serotonin reuptake inhibitors: a literature review. J Clin Psychiatry 1997; 58:291-297.
• 13.0 AUTHOR INFORMATION
• 13.1 CONTRIBUTOR(S) TO THIS DOCUMENT
• A. Original publication: 10/94
• B. Most recent revision: 02/01
• C. List of contributors:

§               1.  Ingrid Lewis, PharmD

§               2.  Katherine M Hurlbut, MD

§               3.  POISINDEX(R) Editorial Staff

• D. Specialty Board: CNS DRUGS
• Refer to the POISINDEX EDITORIAL BOARD section for more information. (MG1846)

End of Document